Skip to Main Content

Paper Details

Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in <i>KRAS</i> Wild-Type Pancreatic Cancer.
JCO Precis Oncol
20
2021
Gene Fusions, KRAS, KRAS MUT, KRAS MUT pancreatic, KRAS MUT pancreatic adenocarcinomas, KRAS WT, KRAS WT pancreatic adenocarcinoma, KRAS WT tumors, KRAS wild-type (KRAS WT) pancreatic cancers, KRAS-mutated (KRAS MUT) pancreatic, MET fusion, Oncogene fusions, Pancreatic cancers, RNA, adenocarcinoma, crizotinib, gene fusions, pancreatic, pancreatic adenocarcinoma, pancreatic adenocarcinomas, patient, patients, tumors

Datasets

Release 1.2